ADMA
ADMA Biologics, Inc.
$11.07
+3.65% 2026-10-19
Health CareS&P 600
ADMASPY
1W
+8.7%
1M
+21.5%
3M
+26.5%
6M
+1.7%
YTD
-39.3%
1Y
-22.9%
Grades vs sector
Momentum7th pct in sectorF
Momentum
7th pct in sector
12-1 return: -35.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth17th pct in sectorD
Growth
17th pct in sector
Revenue growth (YoY): +2.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value78th pct in sectorB+
Value
78th pct in sector
Forward E/P: 8.8% · EBITDA/EV: 9.1%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability92nd pct in sectorA
Profitability
92nd pct in sector
Profit margin: +33.0% · Return on equity: +41.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$2.5B
P/E (trailing)15.8
P/E (forward)11.7
52-week range7.21 – 20.46
Revenue growth (YoY, latest qtr)+2.0%
Dividend yield0.00%
Analyst consensusBuy (4)
Mean price target$17.00 (+54%)
Valuation & fundamentals
Bottom line
Looks undervalued
Model read-out from the numbers below, not advice. Score +4 (DCF counts double).
▲DCF (base case)above the price by 232%
▲Forward P/E vs sector11.7x vs median 17.6x
•Piotroski F-score5/9
▲Altman Z7.9 (safe)
▲Net debt / EBITDA0.3x
▲Analyst target+54% (4 analysts)
Discounted cash flow
Bear
$16
+47%
growth 15% · disc. 8.7% · term. 2.0%
Base
$37
+232%
growth 26% · disc. 7.7% · term. 2.5%
Bull
$74
+564%
growth 32% · disc. 6.7% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 4% a year for 10 years.
Implied
+4%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
+49%/yr
Revenue, last 5 yrs
+65%/yr
Same inputs as the DCF above: trailing free cash flow 0.1B, 7.7% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.69 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 16th pct
15.8×cheaper
Forward P/E
cheaper
sector median 17.6× · 22nd pct
11.7×cheaper
EV / EBITDA
cheaper
sector median 15.8× · 25th pct
10.9×cheaper
Price / sales
pricier
sector median 3.1× · 70th pct
4.8×pricier
Price / book
pricier
sector median 3.5× · 73rd pct
6.1×pricier
FCF yield
cheaper
sector median 4.1% · 58th pct
4.7%cheaper
Forward EPS $0.94 vs trailing $0.70 (+35% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
64.7%
Operating margin
43.8%
FCF margin
22.7%
Net margin
33.0%
Return on equity
41.4%
Return on invested capital
37.4%
Net debt / EBITDA
0.3×
Current ratio
7.0×
Interest cover
25.4×
Cash conversion (OCF/NI)
0.8×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✗ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✓ Gross margin improved✗ Asset turnover improved
Altman Z-score 7.9 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$17
+54%
Analysts
4
Buy
Range
$12–$21
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $510.2M | $146.9M | $27.8M |
| 2024 | $426.5M | $197.7M | $110.4M |
| 2023 | $258.2M | $-28.2M | $4.0M |
| 2022 | $154.1M | $-65.9M | $-73.4M |
| 2021 | $80.9M | $-71.6M | $-125.9M |
| 2020 | $42.2M | $-75.7M | $-114.7M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +49.0%.
Earnings
Next report: 2026-11-04 · during market · EPS est 0.19
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | 0.16 | 0.17 | +3.5% |
| 2026-05-06 | 0.20 | 0.17 | -15.2% |
| 2026-02-25 | 0.20 | 0.22 | +7.8% |
| 2025-11-05 | 0.16 | 0.16 | +2.6% |
| 2025-08-06 | 0.14 | 0.14 | +7.4% |
| 2025-05-07 | 0.17 | 0.11 | -33.3% |
| 2025-03-03 | 0.15 | 0.14 | -9.3% |
| 2024-11-07 | 0.13 | 0.15 | +15.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $124.4M | +2.0% |
| 2026-03-31 | $114.5M | – |
| 2025-12-31 | $139.2M | – |
| 2025-09-30 | $134.2M | – |
| 2025-06-30 | $122.0M | – |
Analyst actions
Mizuho
PT $17
2026-07-15 · main
Outperform → OutperformPT $17
Canaccord Genuity
PT $18
2026-05-07 · main
Buy → BuyPT $18
Mizuho
PT $20
2026-05-07 · main
Outperform → OutperformPT $20
Canaccord Genuity
PT $21
2026-04-21 · init
→ BuyPT $21
Mizuho
PT $24
2026-04-13 · main
Outperform → OutperformPT $24
Cantor Fitzgerald
2026-03-26 · down
Overweight → NeutralInsider trades
None
–
None · None
SELL–
News
How Investors May Respond To ADMA Biologics (ADMA) Peer‑Reviewed Validation Of IVIG Safety And Purity
Simply Wall St. · Oct 15
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
GlobeNewswire · Oct 15
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Zacks · Oct 12
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Zacks · Oct 09
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
Zacks · Oct 08
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Zacks · Oct 08
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Zacks · Sep 29
ADMA Biologics (ADMA), Why Is It Back In The Spotlight?
Simply Wall St. · Sep 27
Stats refreshed 2026-10-19 19:02:34 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.